Anti-mouse CD4-InVivo

製品コード：A2101         Batch: A210118

印刷

Anti-mouse CD4 antibody(Clone:GK1.5) reacts with mouse CD4, which is a 55 kDa cell surface type I membrane glycoprotein. CD4 is a co-receptor of the T cell receptor (TCR) and assists the latter in communicating with antigen-presenting cells.

製品説明

Formulation PBS buffer, pH 6.5
Clone GK1.5
Immunogen

Mouse CTL clone V4
Isotype Rat IgG2b,κ
Application In vivo CD4+ T cell depletion,FCM,WB
Storage
(From the date of receipt)		 Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles
Shipping Shipped under low temperature conditions
Sterility 0.2 μM filtered
Purity 99%
Protein concentration 7.66 mg/mL
Endotoxin Level ＜1 EU/mg

カスタマーフィードバック

Selleckの高級品が、幾つかの出版された研究調査結果（以下を含む）で使われた：

Dual impacts of serine/glycine-free diet in enhancing antitumor immunity and promoting evasion via PD-L1 lactylation [ Cell Metab, 2024, S1550-4131(24)00415-7] PubMed: 39577415
Blockage of L2HGDH-mediated S-2HG catabolism orchestrates macrophage polarization to elicit antitumor immunity [ Cell Rep, 2024, 43(6):114300] PubMed: 38829739
HVEM in acute lymphocytic leukemia facilitates tumour immune escape by inhibiting CD8+ T cell function [ Cell Oncol (Dordr), 2024, 10.1007/s13402-024-00959-1] PubMed: 38809326
Human/mouse CD137 agonist, JNU-0921, effectively shrinks tumors through enhancing the cytotoxicity of CD8+ T cells in cis and in trans [ Sci Adv, 2024, 10(34):eadp8647] PubMed: 39178257
Low-dose radiotherapy combined with dual PD-L1 and VEGFA blockade elicits antitumor response in hepatocellular carcinoma mediated by activated intratumoral CD8+ exhausted-like T cells [ Nat Commun, 2023, 14(1):7709.] PubMed: 38001101
Low-dose radiotherapy combined with dual PD-L1 and VEGFA blockade elicits antitumor response in hepatocellular carcinoma mediated by activated intratumoral CD8+ exhausted-like T cells [ Nat Commun, 2023, 14(1):7709] PubMed: 38001101
Oncolytic virus M1 functions as a bifunctional checkpoint inhibitor to enhance the antitumor activity of DC vaccine [ Cell Rep Med, 2023, 4(10):101229] PubMed: 37820722
Oncolytic virus M1 functions as a bifunctional checkpoint inhibitor to enhance the antitumor activity of DC vaccine [ Cell Rep Med, 2023, 4(10):101229] PubMed: 37820722
Engineering irradiated tumor-derived microparticles as personalized vaccines to enhance anti-tumor immunity [ Cell Rep Med, 2023, 4(12):101303.] PubMed: 38029750
Engineering irradiated tumor-derived microparticles as personalized vaccines to enhance anti-tumor immunity [ Cell Rep Med, 2023, 4(12):101303] PubMed: 38029750

人間や獣医の診断であるか治療的な使用のためにでない。